drugset / Trial / NCT05724472
Evaluation of Safety and Immunogenicity of rVSVΔG-SEBOV-GP Vaccine in Adults With Good General Health
Phase 1
Completed
36 enrolled
International AIDS Vaccine Initiative
Biomedical Advanced Research and Development Authority · collab
RandomizedParallel-groupSingle-blindPrevention
Summary
A Phase 1, Single-blind, Placebo-controlled, Dose-escalation Clinical Trial to Evaluate the Safety and Immunogenicity of rVSVΔG-SEBOV-GP Vaccine at 3 Dose Levels in Adults in Good General Health
Timeline
- Start
- 2023-06-19
- Primary completion
- 2024-01-09
- Completion
- 2024-01-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | rVSV∆G-SEBOV-GP Vaccine | Vaccine | 2e+06 unknown | Intramuscular |
| Subject | rVSV∆G-SEBOV-GP Vaccine | Vaccine | 2e+07 unknown | Intramuscular |
| Subject | rVSV∆G-SEBOV-GP Vaccine | Vaccine | 2e+08 unknown | Intramuscular |